Boston Therapeutics Reports Positive Phase II Results of PAZ320 Are Published in July/August Issue of Endocrine Practice
04 sept. 2013 07h00 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Sep 4, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrates to treat diabetes and...
Boston Therapeutics Reports Financial Results and Corporate Update for the Second Quarter and Six Months Ended June 30, 2013
09 août 2013 10h58 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Aug 9, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a drug development company focused on complex carbohydrates to...
Boston Therapeutics to Exhibit at 2013 American Association of Diabetes Educators Annual Meeting & Exhibition in Philadelphia
02 août 2013 07h30 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Aug 2, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a pharmaceutical company developing and commercializing complex...
Boston Therapeutics Reports First Quarter 2013 Results
15 mai 2013 16h10 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - May 15, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a pharmaceutical company developing and commercializing complex...
Boston Therapeutics Requests an IND Meeting With the FDA for PAZ320 to Reduce Postprandial Hyperglycemia in Type 2 Diabetes
11 avr. 2013 07h00 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Apr 11, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a pharmaceutical company developing and commercializing complex...
Boston Therapeutics Featured in Four Publications
08 avr. 2013 07h50 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwired - Apr 8, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a pharmaceutical company focused on developing and...
Boston Therapeutics Reports Full Year 2012 Financial Results
04 avr. 2013 16h10 HE
|
Boston Therapeutics, Inc.
MANCHESTER, NH--(Marketwired - Apr 4, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrates to treat diabetes and...
Boston Therapeutics Strategically Positioned to Focus Its Pipeline on Commercializing Pharmaceutical Drugs to Treat Diabetes and Inflammatory Disease: To Accelerate Commercialization of PAZ320 & IPOXYN(TM)
27 mars 2013 07h00 HE
|
Boston Therapeutics, Inc.
MANCHESTER, NH--(Marketwire - Mar 27, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a pharmaceutical company focused on developing and commercializing...
Boston Therapeutics Appoints Peter Sheehan, M.D. as Medical Director
12 mars 2013 07h00 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwire - Mar 12, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrates to treat diabetes and...
Boston Therapeutics Reports Positive Phase ll Clinical Trial Results of PAZ320 in Patients With Type 2 Diabetes
26 févr. 2013 07h00 HE
|
Boston Therapeutics
MANCHESTER, NH--(Marketwire - Feb 26, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrates to treat diabetes and...